Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Milan Terl"'
Autor:
Petr Vaník, Jakub Novosad, Olga Kirchnerová, Irena Krčmová, Milan Teřl, Czech Anti-IgE Registry collaborators
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 16, Iss 1, Pp 1-16 (2020)
Abstract Background Omalizumab is an efficient drug for patients with uncontrolled severe allergic asthma (SAA). However, little is known about the differences in omalizumab treatment outcomes among patients with different types of atopic sensitizati
Externí odkaz:
https://doaj.org/article/f695b78f5cc9485db3ee44cdee54cc99
Publikováno v:
Dermatologic Therapy. 33
Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients
Publikováno v:
The Journal of asthma : official journal of the Association for the Care of Asthma. 57(8)
Objective: To describe the characteristics and management of asthma in clinical practice in the Czech Republic in the context of international guidelines and clinical realities.Methods: Data were c...
Autor:
Jana Klosova, Petr Vanik, Jaromir Zatloukal, Olga Ruzickova-Kirchnerova, Irena Krčmová, Eva Vernerova, Dagmar Kindlová, Jan Chlumsky, Vratislav Sedlák, Milan Terl, Petr Pohunek, Jaromir Bystron, Bronislava Novotná, Beata Hutyrova, Petr Panzner, Martina Vasakova
Publikováno v:
Allergy and immunology.
Introduction: Omalizumab is indicated for the treatment of severe allergic bronchial asthma and chronic spontaneous urticaria, although number of studies confirmed the efficacy of this therapy also on other IgE-mediated diseases. The aim of this stud